Evidence map›Paper›PMID 24459612›Full record

ArticlePLoS currents2013

A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.

Hugh D Allen, Kevin M Flanigan, Philip T Thrush, Igor Dvorchik, Han Yin, Charles Canter, Anne M Connolly, Mark Parrish, Craig M McDonald, Elizabeth Braunlin and 4 more

Erratum issued Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLoS currents, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01982695 (Compare Efficacy of the Angiotensin Converting Enzyme Inhibitor), which is not on this map. Cited by 44 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 5 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01982695 nacompletednot on this map

Compare Efficacy of the Angiotensin Converting Enzyme Inhibitor (ACEi) Lisinopril With Angiotensin II Receptor Antagonist Losartan (ARB) for the Cardiomyopathy of Duchenne Muscular Dystrophy

TypeinterventionalSponsorNationwide Children's HospitalRan2009 to 2013Enrolled23ConditionsDuchenne Muscular Dystrophy (DMD), CardiomyopathyArmsLosartan, Lisinopril
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 5 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. An evidence-based systematic review of the off-label uses of lisinopril.British journal of clinical pharmacology · 2018
    Pooled it
  4. Pooled it
  5. Guideline
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Hugh D AllenCenter for Gene Therapy, Heart Center, and Wellstone Cooperative Muscular Dystrophy Research Center, Nationwide Children's Hospital, Columbus, Ohio, USA; Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA; Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
Kevin M FlaniganDepartments of Neurology and Pediatrics, The Ohio State University, Columbus, Ohio, United States; Center for Gene Therapy, Nationwide Children's Hospital, Columbus, Ohio, United States.
Philip T ThrushCenter for Gene Therapy, Heart Centre, and Wellstone Cooperative Muscular Dystrophy Research Center, Nationwide Children's Hospital, Columbus, Ohio, USA; Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA.
Igor DvorchikCenter for Mathematical Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA; Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA.
Han YinCenter for Mathematical Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA; Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA.
Charles CanterSt. Louis Children's Hospital, Washington University College of Medicine, St. Louis, Missouri, USA.
Anne M ConnollySt. Louis Children's Hospital, Washington University College of Medicine, St. Louis, Missouri, USA.
Mark ParrishUniversity of California Davis, Davis, California, USA.
Craig M McDonaldUniversity of California Davis, Davis, California, USA.
Elizabeth BraunlinThe University of Minnesota College of Medicine, Minneapolis, Minnesota, USA.
Steven D ColanBoston Children's Hospital, Harvard Medical School, Boston, USA.
John DayThe University of Minnesota College of Medicine, Minneapolis, Minnesota, USA.
Basil DarrasBoston Children's Hospital, Harvard College of Medicine, Boston, Massachusetts, USA.
Jerry R MendellDepartments of Neurology and Pediatrics, The Ohio State University, Columbus, Ohio, USA; Center for Gene Therapy, Nationwide Children's Hospital, Columbus, Ohio, USA.
The Ohio State University · USSt. Louis Children's Hospital · USUniversity of California, Davis · USUniversity of Minnesota · USBaylor College of Medicine · USBoston Children's Hospital · USHarvard University · USNationwide Children's Hospital · US

Funding

The Ohio State University Center for clinical and Translational ScienceUL1TR001070 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2013 to 2017
$22.6M
NCATS NIH HHS UL1 TR001070
6 · The paper itself

Abstract

objectivesThis study sought to compare the effectiveness and safety of an angiotensin converting enzyme inhibitor (ACE-I) (lisinopril) vs. an angiotensin receptor blocker (ARB) (losartan) for the treatment of cardiomyopathy (CM) in boys with Duchenne muscular dystrophy (DMD).

backgroundDevelopment of CM is universal in boys with DMD. ACE-I and ARB have both been suggested as effective treatment options. ARBs have been associated with skeletal muscle regeneration in a mouse model of DMD. The question of which, if either, is more effective for CM treatment in DMD remains. The purpose of this multicenter double-blind prospective study was to compare efficacy and safety of lisinopril versus losartan in the treatment of newly diagnosed CM in boys with DMD.

methodsEchocardiographic technician inter- and intraobserver variability were tested on 2 separate days on 2 different boys with DMD CM. Results were compared with paired t-testing. Twenty-two boys with newly diagnosed DMD CM (echocardiographic ejection fraction (EF) 10% EF drop. Three boys in the aCE-I group had 3 visits, due to study funding termination. Two were withdrawn because of low EF. All their data are included in the analysis for as long as they remained in the study. Mean EF's were similar at baseline (47.5%- ACE-I, 48.4%- ARB). After 1 year each group significantly improved to 54.6% and 55.2% respectively (p=.02). There was no difference between the 2 treatment groups at 1 year.

conclusionsInter-observer and intra-observer reliability studies showed no differences between echocardiographers on serial examinations. EF improved equally in the two groups. There is no therapeutic difference in EF improvement between lisinopril and losartan over the one-year duration for treatment of boys with DMD-related CM.

trial registrationClinicalTrials.gov NCT01982695.

Identifiers

PMID24459612
PMCPMC3871420
OpenAlexW2015115844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.